Equillium to Present at the Stifel Healthcare Conference
Equillium (Nasdaq: EQ) has announced its participation in the upcoming Stifel Healthcare Conference in New York on November 18-19, 2024. The company will present on Tuesday, November 19 at 12:40 PM ET, highlighting its clinical programs, including the Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD) and the Phase 2 study of itolizumab in ulcerative colitis. The presentation will be held at the Lotte New York Palace Hotel, with management available for one-on-one meetings. A webcast will be accessible through the company's website with a 90-day replay available.
Equillium (Nasdaq: EQ) ha annunciato la sua partecipazione alla prossima Stifel Healthcare Conference a New York, che si terrà il 18-19 novembre 2024. L'azienda presenterà martedì 19 novembre alle 12:40 ET, evidenziando i suoi programmi clinici, incluso lo studio di Fase 3 EQUATOR di itolizumab per la malattia acuta da trapianto contro ospite (aGVHD) e lo studio di Fase 2 di itolizumab nella colite ulcerosa. La presentazione si svolgerà presso il Lotte New York Palace Hotel, con i dirigenti disponibili per incontri individuali. Una registrazione della presentazione sarà accessibile tramite il sito web dell'azienda con una riproduzione disponibile per 90 giorni.
Equillium (Nasdaq: EQ) ha anunciado su participación en la próxima Stifel Healthcare Conference en Nueva York, que se llevará a cabo del 18 al 19 de noviembre de 2024. La empresa presentará el martes 19 de noviembre a las 12:40 PM ET, destacando sus programas clínicos, incluida la estudio de Fase 3 EQUATOR de itolizumab en la enfermedad injerto contra huésped aguda (aGVHD) y el estudio de Fase 2 de itolizumab en colitis ulcerosa. La presentación se llevará a cabo en el Lotte New York Palace Hotel, con la dirección disponible para reuniones uno a uno. Una transmisión en vivo estará disponible a través del sitio web de la empresa con una repetición disponible por 90 días.
Equillium (Nasdaq: EQ)는 2024년 11월 18-19일 뉴욕에서 열리는 Stifel Healthcare Conference에 참여할 것이라고 발표했습니다. 회사는 11월 19일 화요일 오후 12:40 ET에 이탈리주맙의 급성 이식편 대 숙주 질환(aGVHD)에 대한 3상 EQUATOR 연구와 궤양성 대장염에 대한 2상 연구를 포함한 임상 프로그램을 강조하는 프레젠테이션을 진행할 예정입니다. 발표는 Lotte New York Palace Hotel에서 진행되며, 경영진은 일대일 미팅이 가능합니다. 회사 웹사이트를 통해 웹캐스트가 제공되며, 90일 동안 재생할 수 있습니다.
Equillium (Nasdaq: EQ) a annoncé sa participation à la prochaine Stifel Healthcare Conference à New York, qui se déroulera les 18 et 19 novembre 2024. L'entreprise présentera le mardi 19 novembre à 12h40 ET, en mettant en avant ses programmes cliniques, y compris l'étude de Phase 3 EQUATOR sur l'itolizumab dans la maladie aiguë du greffon contre l'hôte (aGVHD) et l'étude de Phase 2 sur l'itolizumab dans la colite ulcéreuse. La présentation se tiendra à l'Hôtel Lotte New York Palace, avec la direction disponible pour des réunions individuelles. Un webcast sera accessible via le site internet de l'entreprise, avec une rediffusion disponible durant 90 jours.
Equillium (Nasdaq: EQ) hat seine Teilnahme an der bevorstehenden Stifel Healthcare Conference in New York am 18.-19. November 2024 angekündigt. Das Unternehmen wird am Dienstag, den 19. November um 12:40 Uhr ET präsentieren und dabei seine klinischen Programme hervorheben, einschließlich der Phase 3 EQUATOR-Studie von Itolizumab bei akuter Graft-versus-Host-Krankheit (aGVHD) und der Phase 2-Studie von Itolizumab bei Colitis ulcerosa. Die Präsentation findet im Lotte New York Palace Hotel statt, wobei das Management für Einzelgespräche zur Verfügung steht. Ein Webcast wird über die Website des Unternehmens zugänglich sein, mit einer 90-tägigen Wiederholung.
- None.
- None.
Management will provide an overview of the Company’s clinical programs, currently focused on the Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD) and the Phase 2 study of itolizumab in ulcerative colitis. Management will be available for one-on-one meetings during the conference.
Conference: |
Stifel Healthcare Conference |
|
Location: |
Lotte New York Palace Hotel |
|
Dates: |
Monday, November 18 & Tuesday, November 19 |
|
Presentation: |
Tuesday, November 19 at 9:40 am Pacific Time | 12:40 pm Eastern Time |
|
Webcast access for the conference will be available on the Events & Presentations page under the Investor Relations tab on the Company’s website. An archived replay of both presentations will be available for 90 days.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel first-in-class immunomodulatory assets and product platform targeting immuno-inflammatory pathways. Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells that drive a number of immuno-inflammatory diseases; currently under evaluation in a Phase 3 clinical study of patients with acute graft-versus-host disease (aGVHD) and announced positive data from a Phase 1b clinical study of patients with lupus/lupus nephritis in April 2024. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited, who also provides commercial manufacturing for the product. EQ101: a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15; recently announced positive results from a Phase 2 proof-of-concept clinical study of patients with alopecia areata. EQ302: an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21 at pre-clinical stage.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", “could”, “continue”, "expect", "estimate", “may”, "plan", "outlook", “future” and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical studies; and whether the results from clinical studies will validate and support the safety and efficacy of Equillium’s product candidates. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website at www.sec.gov and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113328934/en/
Investor Contact
Michael Moore
Vice President, Investor Relations & Corporate Communications
619-302-4431
ir@equilliumbio.com
Source: Equillium, Inc.
FAQ
When is Equillium (EQ) presenting at the Stifel Healthcare Conference 2024?
What clinical trials will Equillium (EQ) discuss at the Stifel Conference?
Where can investors watch Equillium's (EQ) Stifel Conference presentation?
What is the location of Equillium's (EQ) Stifel Healthcare Conference presentation?
